miR-181a modulates acute myeloid leukemia susceptibility to natural killer cells

Although daunorubicin (DNR) is the most widely used anthracycline to treat acute myeloid leukemia (AML), resistance to this drug remains a critical problem. The aim of this study was to investigate the relationship between AML resistance to daunorubicin and susceptibility to natural killer (NK) cell...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncoimmunology
Egile Nagusiak: Nanbakhsh, Arash, Visentin, Géraldine, Olive, Daniel, Janji, Bassam, Mussard, Eugenie, Dessen, Philippe, Meurice, Guillaume, Zhang, Yanyan, Louache, Fawzia, Bourhis, Jean-Henri, Chouaib, Salem
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2015
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4635878/
https://ncbi.nlm.nih.gov/pubmed/26587335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2014.996475
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak